EGFR and head and neck squamous cell carcinoma: One of such trials is underway to test the safety of the intratumoral administration of autologous T-cells engineered to express a second generation CAR able to engage multiple ErbB dimers that are commonly upregulated in HNSCC (163; Table 2).